November 2017– GEN (Genetic Engineering & Biotechnology News) publishes an interview of Leo Price, CEO, in Feature Article:

“High-Content Analysis through 3D Screening

Visualization Tools Can Improve Cell-Therapy Products, Drug Screens, and Gene-Function Profiles”

Click here to read the entire article


June 2017 – OcellO’s 3D in vitro assay for Polycystic Kidney Disease  (PKD) is now published in SLAS Discovery (previously Journal of Biomolecular Screening). The article describes application of OcellO’s 3D screening platform on the organoid assay in combination with a large kinase inhibitor library. This led to the discovery of novel potential targets as well as mechanistic insight into the role of existing pathways in cyst development.


October 2016“Stay in Step with the ‘Crazy Pace’ of High-Content Screening Advances” is an article issued from the SLAS Europe High-Content Screening Conference held in Dresden in June 2016 where OcellO presented the work recently published in JBS.


September 2016 –  Applying 3D cell culture and other innovative technologies in Modern Drug Discovery. Read the Nature Drug Discovery Reviews article co-authored by OcellO’s CEO, Leo Price.


August 2016 –  A publication in the Journal of Biomolecular Screeening describes the phenotypic profiling of c-Met and EGFR receptor tyrosine kinase inhibitors. 3D culture of prostate tumour tissues is combined with 3D imaging and multiparametric image analysis to discriminate selective c-Met and EGFR inhibitors and discriminate compounds with off-target activity.  OcellO can apply this approach to screen compound collections for their activity against diverse cellular targets.  Follow this link to access this open access manuscript.


OcellO Key publications

Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases. Booij TH, Klop MJ, Yan K, Szántai-Kis C, Szokol B, Orfi L, van de Water B, Keri G, Price LS. J Biomol Screen. 2016 Jul 7. pii: 1087057116657269

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH. Genes Cancer. 2015 Nov;6(11-12):503-12.

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EHJ Pathology. 2015 Jul;236(3):348-59. doi: 10.1002/path.4528. Epub 2015 Mar 30.

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling. Sandercock AM, Rust S, Guillard S, Sachsenmeier KF, Holoweckyj N, Hay C, Flynn M, Huang Q, Yan K, Herpers B, Price LS, Soden J, Freeth J, Jermutus L, Hollingsworth R, Minter R. Mol. Cancer. 2015 Jul 31;14:147.

Zi D, Klop M, Vasiliki MR, Le Dévédec SE, van de Water B, Verbeek F, Price LS & Meerman J (2014). Ultra high content image analysis and phenotype profiling of 3D cultured micro-tissues. PLOSone, 2014 PLoS One. 7;9(10):e109688.

Ramaiahgari S, den Braver M, Herpers B, Terpstra V, Commandeur J, van de Water B, Price LS (2014). A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol. 88(5):1083-95

Stokman G, Qin Y, Booij T, Ramaiahgari S, Lacombe M, Dolman M, van Dorenmalen K, Teske G, Florquin S, Schwede F, van de Water B, Kok R, Price LS (2014). Epac-Rap signaling reduces oxidative stress in the tubular epithelium. 2014. J Am Soc Nephrol. 25(7):1474-85.

Truong H, de Sonneville J, Ghotra V, Xiong J, Price LS, Hogendoorn P, Spaink H, van de Water B, Danen E (2012). Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. Biomaterials; 33(1):181-8.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price LS, Meerman J, van de Water B (2011). Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.  Breast Cancer Res.; 19;13(3)